Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cephalon Option To Buy Biologics Firm Ception Gets The Ball Rolling For 2009, CEO Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Look for Cephalon to “roll up” more assets this year while the market is good, CEO Baldino says at J.P. Morgan.

You may also be interested in...



Second Time Around: Cephalon Buys Ception Based On Cinquil Data In Asthma

Cephalon passed on a first option to buy Ception Therapeutics, but will now acquire the company for $250 million following encouraging Phase II results.

Second Time Around: Cephalon Buys Ception Based On Cinquil Data In Asthma

Cephalon passed on a first option to buy Ception Therapeutics, but will now acquire the company for $250 million following encouraging Phase II results.

Partnering Inflammation/Autoimmune Drugs Offers Sizzle And Steak

As Big Pharma companies back away from developing primary care products because of rising development costs and regulatory risk, they are increasingly turning to specialty medicines to fill their pipeline holes. One therapeutic area of particular interest: the inflammation/auto-immune space

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS068472

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel